Duska Therapeutics Names Dr. James S. Kuo as CEO
BALA CYNWYD, PA -- Oct 3, 2007 -- Duska Therapeutics a biopharmaceutical company developing new medicines to treat cardiovascular diseases, announced today that James S. Kuo, M.D., M.B.A., has joined the Company as Chief Executive Officer. Dr. Kuo is also currently Chairman of the Board of Directors.
Dr. Kuo has been the CEO of several biotech companies, a venture capitalist, and a business development executive. Most recently, he was Chairman and CEO of BioMicro Systems, a privately held company that developed and commercialized molecular biology research tools. He has also been CEO of Discovery Laboratories, a publicly traded biopharmaceutical company developing respiratory surfactants. Previously, Dr. Kuo was Managing Director of Venture Analysis with HealthCare Ventures. In addition, he has been a licensing and development executive with Pfizer, Inc. Dr. Kuo received his medical degree from University of Pennsylvania and his M.B.A. from The Wharton School of Business at the University of Pennsylvania.
Dr. Amir Pelleg, Duska's President and Chief Scientific Officer said, "I have closely worked with Jim over the last few months in his role as Chairman of the Board. I enthusiastically welcome his added role as CEO. With his experience building successful biotech companies, his skill set is exactly what Duska needs to rapidly move to the next level."
About Duska Therapeutics, Inc.
Duska Therapeutics, Inc, based in Bala Cynwyd, Pennsylvania, develops new medicines to treat cardiovascular diseases by modulating the P2 receptor in the heart and lungs. In addition to ATPaceâ„¢, (adenosine triphosphate injection) for the treatment and diagnosis of certain cardiac arrhythmias, Duska has drug development programs targeting chronic obstructive pulmonary disorders and cough, male infertility and mitigating the toxic effects of radiation exposure. For more information, visit Duska's website: www.duskatherapeutics.com.
Forward-Looking Statement: This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and certainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to the early stage of Duska's drug development projects, Duska's limited financial resources and its need to raise additional capital to fund its ongoing working capital and drug development needs, the need for future clinical testing of Duska's drug candidates, uncertainties regarding the scope of the clinical testing that may be required by regulatory authorities and the outcomes of those tests, the significant time and expense that will be incurred in developing any of the potential commercial applications for Duska's P2R technologies, risks relating to the enforceability of any patents covering Duska's products and to the possible infringement of third party patents by those products, and the impact of third party reimbursement policies on the use of and pricing for Duska's products. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. All forward-looking statements are based upon information available to Duska on the date the statements are first published. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.